The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

RÁČIL, Zdeněk, Filip RÁZGA, Lucie BUREŠOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Shira TIMILSINA, Petr CETKOVSKÝ and Jiří MAYER. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. American Journal of Hematology. 2010, vol. 85, No 7, p. 525-528. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.21722.

Basic information

• Original name: The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
• Authors: RÁČIL, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Filip RÁZGA (703 Slovakia, belonging to the institution), Lucie BUREŠOVÁ (203 Czech Republic, belonging to the institution), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Shira TIMILSINA (203 Czech Republic, belonging to the institution), Petr CETKOVSKÝ (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution).
• Edition: American Journal of Hematology, 2010, 0361-8609.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United States of America
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 3.576
• RIV identification code: RIV/00216224:14110/10:00067349
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1002/ajh.21722
• UT WoS: 000279506200018
• Keywords in English: RESIDUAL DISEASE DETECTION; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; CANCER PROGRAM; OCT-1 ACTIVITY; IMATINIB; RESISTANCE; DETERMINANT; EUROPE
• Tags: International impact, Reviewed

Abstract

The monitoring of hOCT1 mRNA expression in patients with chronic myelogenous leukemia (CML) was used for predicting the response to imatinib treatment. However, different cell populations from patients who received various degrees of pretreatment were used for this analysis. Therefore, several biases in the results and their interpretation may arise. We investigated hOCT1 mRNA expression in different cell populations of peripheral blood (PB) from healthy volunteers and in imatinib nave de novo CML patients by analyzing changes in hOCT1 mRNA expression during the first 6 months of imatinib therapy. The hOCT1 mRNA expression was significantly higher in PB polymorphonuclears compared to mononuclears. The hOCT1 mRNA expression in total PB leukocytes is, therefore, preferentially determined by the percentage of polymorphonuclears. Expression in each analyzed group of cells was always significantly lower in imatinib nave de novo CML patients compared to healthy volunteers. This difference disappeared after the initiation of imatinib therapy, suggesting that CML tumor burden and the degree of pretreatment at the time of monitoring were both influencing factors.

Links

• MSM0021622430, plan (intention): Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies